Pivot Pharmaceuticals Inc

Pivot Pharmaceuticals Inc

  • Price (EUR)0.0785
  • Today's Change-0.004 / -4.27%
  • Shares traded0.00
  • 1 Year change-69.81%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2019 09:30 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Pivot Pharmaceuticals Inc., formerly Neurokine Pharmaceuticals Inc., is a development-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic pharmaceutical products. The Company is in the business of developing and commercializing new uses for existing prescription drugs, as well as developing encapsulation technology in the treatment of neurodegenerative diseases. The Company's research and development activities are focused on advancing drug candidates for the treatment of women's cancers, including, but not limited to metastatic endometrial cancer and triple-negative breast cancer; leveraging drug delivery treatment options to allow targeted delivery of drugs to address women's health needs in urological and/or gynecological indications, and opportunistically in-licensing later-stage drug candidates to augment its drug pipeline.

  • Revenue in CAD (TTM)--
  • Net income in CAD--
  • Incorporated2002
  • Employees0.00
  • Location
    Pivot Pharmaceuticals Inc1275 6th Ave WVANCOUVER V6H 1A6CanadaCAN
  • Phone+1 51 4943 1899
  • Fax+1 60 4551 5178
  • Websitehttps://pivotpharma.com/
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.